Search
for
Sort by
Research 31–60 of 229
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Sterol Intermediates of Cholesterol Biosynthesis Inhibit Hair Growth and Trigger an Innate Immune Response in Cicatricial Alopecia
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Janus kinase inhibitors for alopecia areata: A narrative review
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- JAK inhibitors in dermatology: The promise of a new drug class
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Under Development JAK Inhibitors for Dermatologic Diseases
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects